Wall Street analyst estimates for GSK plc (GSK): consensus price target and buy/hold/sell recommendations.
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 16 |
| Sell | 4 |
| Strong Sell | 0 |
| Total analysts | 29 |
| Avg rating (−2 sell to +2 buy) | 0.17 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-03 | $0.78 | ||
| 2026-10-28 | $1.47 | $1.33 | +10.5% |
| 2026-07-28 | $1.36 | $1.27 | +7.1% |
| 2026-04-29 | $1.24 | $1.16 | +6.9% |
| 2026-02-04 | $0.68 | $0.64 | +6.3% |
| 2025-10-29 | $1.48 | $1.26 | +17.5% |
| 2025-07-30 | $1.23 | $1.12 | +9.8% |
| 2025-04-30 | $1.13 | $1.08 | +4.6% |
Valuation Ratios
| P/E Ratio | 15.26 |
| Price / Book | 4.17 |
| EV / EBITDA | 8.62 |
| Dividend Yield | 3.71% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.89B GBP | 30.19B GBP | 30.82B GBP | 33.75B GBP | 24.35B GBP | 24.70B GBP | 29.32B GBP | 30.33B GBP | 31.38B GBP | 32.67B GBP |
| Cost of Revenue | 9.29B GBP | 10.34B GBP | 10.24B GBP | 11.86B GBP | 7.93B GBP | 8.16B GBP | 9.55B GBP | 8.56B GBP | 9.05B GBP | 9.02B GBP |
| Gross Profit | 18.60B GBP | 19.84B GBP | 20.58B GBP | 21.89B GBP | 16.43B GBP | 16.53B GBP | 19.77B GBP | 21.76B GBP | 22.33B GBP | 23.65B GBP |
| Research & Development | 3.63B GBP | 4.48B GBP | 3.89B GBP | 4.57B GBP | 4.79B GBP | 5.02B GBP | 5.49B GBP | 6.22B GBP | 6.40B GBP | 7.53B GBP |
| Selling, General & Admin | 9.37B GBP | 9.67B GBP | 9.91B GBP | 11.40B GBP | 7.44B GBP | 7.07B GBP | 8.37B GBP | 9.38B GBP | 11.02B GBP | 9.09B GBP |
| Operating Expenses | 16.00B GBP | 15.76B GBP | 15.10B GBP | 14.93B GBP | 10.45B GBP | 12.18B GBP | 13.34B GBP | 15.02B GBP | 18.31B GBP | 15.31B GBP |
| Operating Income | 2.60B GBP | 4.09B GBP | 5.48B GBP | 6.96B GBP | 5.98B GBP | 4.36B GBP | 6.43B GBP | 6.75B GBP | 4.02B GBP | 8.34B GBP |
| EBITDA | 4.43B GBP | 6.18B GBP | 7.35B GBP | 9.43B GBP | 8.07B GBP | 6.49B GBP | 8.60B GBP | 9.08B GBP | 6.67B GBP | 10.40B GBP |
| Interest Expense | 736.0M GBP | 734.0M GBP | 743.6M GBP | 912.0M GBP | 892.0M GBP | 784.0M GBP | 855.5M GBP | 775.0M GBP | 657.6M GBP | 687.0M GBP |
| Pre-tax Income | 1.94B GBP | 3.52B GBP | 4.80B GBP | 6.22B GBP | 5.17B GBP | 3.60B GBP | 5.63B GBP | 6.06B GBP | 3.48B GBP | 7.40B GBP |
| Income Tax | 877.0M GBP | 1.36B GBP | 754.0M GBP | 953.0M GBP | 67.0M GBP | 83.0M GBP | 707.0M GBP | 756.0M GBP | 526.0M GBP | 1.11B GBP |
| Net Income | 912.0M GBP | 1.53B GBP | 3.62B GBP | 4.64B GBP | 5.75B GBP | 4.38B GBP | 14.96B GBP | 4.93B GBP | 2.58B GBP | 5.72B GBP |
| EPS | $0.48 | $0.78 | $1.84 | $2.34 | $2.88 | $2.74 | $7.44 | $2.44 | $1.26 | $2.82 |
| EPS (Diluted) | $0.46 | $0.78 | $1.82 | $2.32 | $2.86 | $2.70 | $7.32 | $2.40 | $1.24 | $2.78 |
| Shares Outstanding (Diluted) | 1,963.6 M | 1,976.4 M | 1,988.4 M | 2,006.4 M | 2,015.2 M | 1,620.8 M | 2,042.0 M | 2,055.5 M | 2,071.0 M | 2,058.5 M |
Price
| Price | $48.74 (closing price, October 28, 2026) |
| Market Cap | $97.7B |
| Exchange | NYSE |
| Country | GB |
Related companies: MRK · AMGN · SNY · LLY · JNJ · AZN · NVS · NVO
Explore sector: Healthcare · Drug Manufacturers - General
More sections of GSK: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks